| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee1c19da359446fb5c4f0458a57b783d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 |
| filingDate |
1993-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1998-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97f6b4615bdcc7151ac3cfcabd87ca7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edfd53e40351ec991c556bc209eb873c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f2c7a2f0820009900a031bd32b2b881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a37c568d54dd32e0f90875fd4410982
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb64ed90093dd7cf9a3ab517c9ad8355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c86ff2d135b72f3a7d577ab6b530a3e |
| publicationDate |
1998-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-0156948-B1 |
| titleOfInvention |
Isoindazole Compound |
| abstract |
Isoidazole compound of the following general formula (1) or its salt; Its production method; And the pharmaceutical use of said compound chi salts thereof in particular as an angiotensin II antagonist and a prophylactic and therapeutic agent for circulatory diseases (especially hypertension and heart failure);n n n n n n n n [Wherein Q is a heterocyclic derivative of the following general formula (2) or (3).]n n n n n n n n n n n n n (Wherein, the other symbols of the above general formula are as defined in the specification)n n n The compound and its salts show good angiotensin II antagonism and have low toxicity. That is, they are useful as angiotensin II antagonists for the treatment or prevention of angiotensin II intervening diseases such as hypertension (eg, essential hypertension, nephrotic hypertension) and heart failure. |
| priorityDate |
1992-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |